利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

82 条记录 (耗时 0.025 秒)

    Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
    11.
    发明公开
    Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues 有权
    塞来昔酮治疗维生素E脱氢表雄酮（DHEA）

    公开(公告)号：EP2386305A2

    公开(公告)日：2011-11-16

    申请号：EP11174933.9

    申请日：1999-06-10

    申请人： ENDORECHERCHE INC.

    发明人： Labrie, Fernand

    IPC分类号： A61K31/565 ,  A61K45/06 ,  A61P3/06 ,  A61P9/00 ,  A61P19/10

    CPC分类号： A61K31/565 ,  A61K31/57 ,  A61K31/66 ,  A61K45/06 ,  A61K31/445 ,  A61K31/41 ,  A61K31/40 ,  A61K31/38 ,  A61K31/135 ,  A61K2300/00

    摘要： Novel methods for the medical treatment and/or inhibition of the development of breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol, and compounds converted in vivo to one of the foregoing precursors.
    Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursors is disclosed. Pharmaceutical compositions for delivery of active ingredients and kits useful to the invention are disclosed.

    摘要翻译： 涉及施用选择性雌激素受体调节剂的敏感温血动物（包括人）在内的用于治疗和/或抑制乳腺癌发展，高胆固醇血症，高脂血症或动脉粥样硬化的新方法，以及选自以下组中的一种性类固醇前体 的脱氢表雄甾酮，硫酸脱氢表雄酮，雄甾-5-烯-3,2α-二醇，以及在体内转化成前述前体之一的化合物。 公开了将二膦酸盐与选择性雌激素受体调节剂和/或性类固醇前体组合的进一步给药。 公开了用于递送用于本发明的活性成分和试剂盒的药物组合物。

    DHEA COMPOSITIONS FOR TREATING MENOPAUSE
    12.
    发明公开
    DHEA COMPOSITIONS FOR TREATING MENOPAUSE 审中-公开
    脱氢表雄酮组合物用于治疗更年期

    公开(公告)号：EP2185157A1

    公开(公告)日：2010-05-19

    申请号：EP08783354.7

    申请日：2008-08-08

    申请人： Endorecherche, Inc.

    发明人： LABRIE, Fernand

    IPC分类号： A61K31/5685 ,  A61K31/453 ,  A61K31/56 ,  A61P15/12 ,  A61P5/26 ,  A61P5/32

    CPC分类号： A61K31/453 ,  A61K9/0014 ,  A61K9/0034 ,  A61K31/56 ,  A61K31/5685

    摘要： Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are disclosed.

    METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES
    17.
    发明授权
    METHOD OF TREATMENT OF ANDROGEN-RELATED DISEASES 失效
    METHOD FOR THE治疗雄激素疾病

    公开(公告)号：EP0595796B1

    公开(公告)日：2003-01-15

    申请号：EP90909601.8

    申请日：1990-07-05

    申请人： ENDORECHERCHE INC.

    发明人： LABRIE, Fernand

    IPC分类号： A61K31/565 ,  A61K31/575 ,  A61K31/57

    CPC分类号： A61K31/575 ,  A61K31/565 ,  A61K31/57 ,  Y02A50/395 ,  Y10S514/80 ,  A61K2300/00

    摘要： A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione ( DELTA 4-dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.

    Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
    19.
    发明公开
    Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia 失效
    联合治疗良性前列腺增生症的预防和/或治疗

    公开(公告)号：EP0943328A2

    公开(公告)日：1999-09-22

    申请号：EP99106510.3

    申请日：1990-07-05

    申请人： ENDORECHERCHE INC.

    发明人： Labrie, Fernand

    IPC分类号： A61K31/135 ,  A61K31/565 ,  A61K45/06

    CPC分类号： A61K31/565 ,  A61K45/06 ,  A61K31/13 ,  A61K2300/00

    摘要： A therapeutic combination, useful in the treatment or prevention of benign prostatic hyperplasia, includes an antiestrogen and at least one further active ingredient selected from the group consisting of inhibitors of aromatase activity and inhibitors of 5α-reductase activity.
    Pharmaceutical compositions and kits useful for such treatment are also provided.

    摘要翻译： 的治疗剂组合，用于治疗或预防良性前列腺增生是有用的，包括至少一个抗雌激素药和选自芳香活性的抑制剂和5α还原酶活性的抑制剂的选择另外的活性成分。 因此，药物组合物和寻求治疗的试剂盒提供。